蓝岑口服液治疗小儿上呼吸道感染的临床应用价值  

Clinical Application Value of Lancen Oral Liquid in Treatment of Children with Upper Respiratory Tract Infection

作　　者：丁甦苹 

机构地区：[1]广东省梅州市丰顺县人民医院儿科,广东梅州514300

出　　处：《中外医疗》2017年第24期140-142,共3页China & Foreign Medical Treatment

摘　　要：目的研究蓝岑口服液治疗小儿上呼吸道感染的临床应用价值。方法方便选取广东省梅州市丰顺县人民医院儿科2016年1月—2017年5月小儿上呼吸道感染患儿120例根据随机数字表法分为两组,每组60例患者,常规组进行常规治疗;蓝岑组在常规组基础上给予蓝岑口服液治疗。就两组患儿治疗前后C反应蛋白、白细胞计数、不同免疫球蛋白水平和上呼吸道感染治疗总有效率、咽部红肿消除时间、鼻塞缓解时间、退热时间、流涕停止时间进行比较。结果蓝岑组上呼吸道感染治疗总有效率93.33%明显高于常规组73.33%(P<0.05)。蓝岑组咽部红肿消除时间、鼻塞缓解时间、退热时间、流涕停止时间(2.51±0.41)、(2.21±0.37)、(2.65±1.41)、(3.31±1.61)d明显低于常规组(3.31±1.72)、(3.31±1.53)、(4.66±2.52)、(5.35±2.57)d(P<0.05)。治疗前两组C反应蛋白、白细胞计数、不同免疫球蛋白水平相似,蓝岑组分别为(10.23±0.71)mg/L、(25.48±8.71)×109/L、(0.76±0.12)g/L(7.21±0.55)g/L,常规组分别为(10.31±0.76)mg/L、(25.16±8.45)×109/L、(0.75±0.13)g/L、(7.21±0.54)g/L(P>0.05)。蓝岑组患儿治疗后C反应蛋白、白细胞计数、不同免疫球蛋白水平(3.24±0.42)mg/L、(8.43±2.14)×109/L、(0.91±0.11)g/L、(7.72±0.52)g/L均明显优于常规组(6.27±0.51)mg/L、(14.01±6.43)×109/L、(0.76±0.11)g/L、(7.34±0.51)g/L(P<0.05)。结论蓝岑口服液治疗小儿上呼吸道感染的临床应用价值高,可有效降低机体炎症水平,促进症状消退,提升免疫力水平,值得推广。Objective To research the application value of Lancen oral liquid in treatment of children with upper respiratory tract infection. Methods 120 cases of children with upper respiratory tract infection treated in our hospital from January2016 to May 2017 were conveniently selected and randomly divided into two groups with 60 cases in each, the routine group adopted the routine treatment, while the Lancen group adopted the lancen oral liquid for treatment on the basis of the treatment, and the C reactive protein, leucocyte count, different immunoglobulin levels, total effective rate of upper respiratory tract infection, elimination time of pharynx swelling, nasal obstruction relief time, defervescence time, rhinorrhoea stopping time were compared. Results The total treatment effective rate of upper respiratory tract infection in lancen group was obviously higher than that in the routine group(93.33% vs 73.33%)(P<0.05), and the elimination time of pharynx swelling,nasal obstruction relief time, defervescence time, rhinorrhoea stopping time in the lancen group were obviously lower than those in the routine group[(2.51±0.41),(2.21±0.37),(2.65±1.41),(3.31±1.61)d vs(3.31±1.72),(3.31±1.53),(4.66±2.52),(5.35±2.57)d](P<0.05), before treatment, the C reactive protein, leucocyte count, different immunoglobulin levels in the lancen group and routine group were similar [(10.23 ±0.71)mg/L,(25.48 ±8.71) ×109/L,(0.76 ±0.12)g/L,(7.21 ±0.55)g/L vs(10.31±0.76)mg/L,(25.16±8.45)×109/L,(0.75 ±0.13)g/L,(7.21±0.54)g/L](P >0.05), after treatment, the C reactive protein,leucocyte count, different immunoglobulin levels in the lancen group were obviously better than those in the routine group[(3.24±0.42)mg/L,(8.43±2.14)×109/L,(0.91±0.11)g/L,(7.72±0.52)g/L vs(6.27±0.51)mg/L,(14.01±6.43)×109/L,(0.76±0.11)g/L,(7.34±0.51)g/L](P<0.05.) Conclusion The clinical application value of lancen oral liquid in treatment of children with upper respiratory tract infection is high, which can reduce the organ inflammatory level, pro

关 键 词：蓝岑口服液 小儿上呼吸道感染 临床应用价值 

分 类 号：R725[医药卫生—儿科]